Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 4/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22708254 | 1.00 | P2RX7 (0.39) | P2RX7ACEPIK3CDNAAAMAPK1 | |
| SCHEMBL7484640 | 1.00 | P2RX7 (0.39) | P2RX7ACEPIK3CDNAAAMAPK1 | |
| SCHEMBL14620630 | 0.82 | P2RX7 (0.41) | P2RX7PIK3CD | |
| SCHEMBL3666651 | 0.82 | P2RX7 (0.39) | P2RX7PIK3CD | |
| Lithium Ion SCHEMBL31694896 | 0.80 | P2RX7 (0.38) | P2RX7MAPK1 | |
| Lithium Ion SCHEMBL31694837 | 0.80 | P2RX7 (0.38) | P2RX7MAPK1 | |
| SCHEMBL31391918 | 0.79 | P2RX7 (0.45) | P2RX7 | |
| SCHEMBL13990350 | 0.79 | P2RX7 (0.40) | P2RX7 | |
| SCHEMBL13863024 | 0.79 | P2RX7 (0.40) | P2RX7 | |
| SCHEMBL3851739 | 0.78 | P2RX7 (0.36) | P2RX7PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4631573-A2 | TEAD INHIBITORS | Orion Corporation (FI) | 2025-10-15 | — | — | EP | disclosed |
| EP-4323338-B1 | TEAD INHIBITORS | ORION CORP (FI) | 2025-10-08 | — | — | EP | disclosed |
| US-20100144727-A1 | Oxazolidine and Morpholine Carboxamide Derivatives as P2X7 Modulators | BESWICK PAUL JOHN | 2010-06-10 | — | — | US | disclosed |
| EP-2139875-A2 | OXAZOLIDINE AND MORPHOLINE CARBOXAMIDE DERIVATIVES AS P2X7 MODULATORS | Glaxo Group Limited (GB) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008119685-A2 | OXAZOLIDINE AND MORPHOLINE CARBOXAMIDE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144727-A1 | Oxazolidine and Morpholine Carboxamide Derivatives as P2X7 Modulators | P2RX5, P2RX3, P2RX7 | P2RX7 3/4885ACE 3655/4885PIK3CD 838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.